share_log

HC Wainwright & Co. Maintains Buy on Bicara Therapeutics, Lowers Price Target to $44

Benzinga ·  Apr 7 11:22

HC Wainwright & Co. analyst Robert Burns maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price target from $45 to $44.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 330

Recommended

Write a comment